“…The use of oral Gastrografin® (Schering, Berlin, Germany), a water-soluble contrast medium, has previously been evaluated to predict the need for surgery, 6,7 to estimate whether it could shorten the resolution of a SBO and the hospital stay related to SBO, 8,9 and to investigate its potential therapeutic value. 8,10 -12 These studies have proved that Gastrografin® has a place in SBO diagnosis, 13 although its therapeutic role is not well-established. 14 The aim of this prospective study was to evaluate, in patients initially treated nonoperatively, the usefulness and the impact of a protocol using CT-scans and oral Gastrografin® in the management of adhesive SBO.…”